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Introduction 
 
Lysine-specific demethylase  (LSD ) catalyzes the demethylation 
of mono- and dimethylated Lys4 of histone H3 through flavin 
adenine dinucleotide (FAD)-dependent enzymatic oxidation [ -3]. 
LSD  regulates epigenetic gene expression that does not involve 
changes in the underlying DNA sequence, and plays key roles in such 
biological functions as embryonic development and homeostasis [4]. 
In particular, LSD  is regarded as a drug target for various cancers, 
including leukemia and colon cancer [4-7]. In addition, it has been 
reported that LSD  is associated with the latent infection of α-
herpesvirus and globin disorder [8,9]. However, the detailed 
biological/physiological roles of LSD  and the association between 
LSD  and oncogenic transformation remain unclear. Therefore, 
compounds that inhibit the catalytic activity of LSD  are interesting 
as chemical tools for studying the functions of LSD  and as candidate 
therapeutic agents targeting LSD . 
trans-2-Phenylcyclopropylamine (PCPA/Tranylcypromine, Chart 
) is one of the best-studied LSD  inhibitors and has contributed 
immensely to the understanding of the biology of  LSD   [6, 0- 3].  
  
 
 
 
 
 
 
 
 
  
 
 
 
PCPA inhibits LSD  irreversibly by forming a  PCPA-FAD  adduct 
through an enzymatic reaction with LSD . However, PCPA has some 
drawbacks, including insufficient inhibitory potency and inadequate 
selectivity for LSD  [ 4], because it was originally found as an 
inhibitor of monoamine oxidases (MAOs), which are also FAD-
dependent enzymes. To this end, many PCPA derivatives have been 
developed to overcome those drawbacks [ 5-20]. 
 
 
 
 
 
Recently, we discovered a novel series of LSD  inactivators 
(NCD series compounds, Chart ) based on the idea of PCPA 
delivery to the LSD  active site [2 ]. The NCD series compounds 
designed by conjugating PCPA with a lysine moiety, an LSD -
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Chart 1.  Structures of PCPA, NCD18, NCD25, and NCD41. 
recognition structure, inactivated LSD  strongly and selectively. 
However, they were synthesized by coupling a lysine moiety with 
racemic trans-PCPA and therefore, optically active NCD compounds 
were not evaluated for their LSD  inhibitory activities. Some LSD  
research groups have investigated the difference in LSD  inhibitory 
activity between the two enantiomers of PCPA and its derivatives 
[ 4,22,23]. Following those results, we decided to examine the 
relationship between the stereochemistry and the LSD  inhibitory 
activities of the NCD series compounds. Here we report the synthesis, 
the LSD  inhibitory activity, and the binding simulation of the 
optically active NCD compounds, with focus on the stereochemistry 
of the PCPA moiety. 
 
Experimental Procedures 
 
Melting points were determined using a Yanagimoto micro 
melting point apparatus, a Büchi 545 melting point apparatus or a 
Yanaco micro melting point apparatus and were left uncorrected. 
Proton nuclear magnetic resonance spectra ( H NMR) and carbon 
nuclear magnetic resonance spectra ( 3C NMR) were recorded on a 
BRUKER AVANCE 300 spectrometer in the indicated solvent. 
Chemical shifts () were reported in parts per million relative to the 
internal standard, tetramethylsilane. Elemental analysis was performed 
with a Yanaco CHN CORDER NT-5 analyzer, and all values were 
within ±0.4% of the calculated values. Fast atom bombardment 
(FAB) mass spectra were recorded on a JEOL JMS-SX 02A mass 
spectrometer. HPLC analysis and Preparative HPLC were performed 
on an ODS-3 ( 50 mm x φ4.6 mm, GL Science or Cosmosil) and an 
Inertsil ODS-3 (250 mm x φ20 mm, GL Science or Cosmosil), 
respectively. The HPLC system was composed of a pump 
(HITACHI, L-6050 intelligent pump) and a detector (HITACHI, 
L-4000 UV detector) Elution of HPLC chromatogram in synthetic 
procedure was done with a linear gradient (eluent, 0 min (30 % 
MeCN/0.  % TFA aq.) – 2 min (30 % MeCN/0.  % TFA aq.) – 
20 min (70 % MeCN/0.  % TFA aq.) – 30 min (70 % MeCN/0.  
% TFA aq.).; flow rate = .0 mL/min). The detection wavelength 
was 254 nm. Optical rotation of optically active compounds was 
measured using a HORIBA Scientific, SEPA-300 polarimeter. 
Reagents and solvents were purchased from Aldrich, Merck, Nacalai 
Tesque, Tokyo Kasei Kogyo, Wako Pure Chemical Industries, 
Kishida Kagaku and Kanto Kagaku, and used without purification. 
Flash column chromatography was performed using Silica Gel 60 
(particle size 0.046–0.063 mm) supplied by Merck. 
 
( S,2R)-PCPA and ( R,2S)-PCPA were separated from 
commercially available trans-(±) PCPA by diastereomeric salt (salt  
or 2) formation method using optically pure tartaric acid [24]. The 
absolute stereostructures were confirmed by specific rotation [ 4,24] 
and H NMR analysis using a chiral shift reagent, ( 8-crown-6)-
2,3, , 2-tetracarboxylic acid [25,26] . 
Optically pure PCPA (6.8–7.0 eq.) and potassium carbonate 
(K2CO3) ( .0 eq.) were added to a solution of corresponding mesylate 
compound 3 ( .0 eq.) in dimethylformamide (DMF) (0.2–0.3 mL) 
and the resulting mixture was stirred at 40–50 °C for 5–22 hours. 
The reaction mixture was diluted with dichloromethane and washed 
with aqueous saturated sodium hydrogen carbonate, brine and dried 
over sodium sulfate. Filtration and purification by silica gel flash 
column chromatography (chloroform/methanol = 00/0 to 50/ ) 
gave optically active NCD 8, NCD25 and NCD4  as crude solids. 
( S,2R)-NCD 8 was purified by preparative HPLC to give an 
optically active form as trifluoroacetic acid (TFA) salt. On the other 
hand, ( R,2S)-NCD 8, ( R,2S)-NCD25, ( S,2R)-NCD25, 
( R,2S)-NCD4  and ( S,2R)-NCD4  were neutralized with 4N 
hydrogen chloride in ethyl acetate and recrystallized from iso-
propanol/diethyl ether (NCD 8) or dichloromethane/diethyl ether 
(NCD25 and NCD4 ) to give optically active forms as 
hydrochloride salts. The detail characterization of each substance is 
described as below.  
( R,2S)-NCD 8 hydrochloride salts: colorless amorphous ( 8.6 
mg, 7%); H NMR (CD3OD, 300MHz, ; ppm) 7.89–7.86 (2H, 
m), 7.55 ( H, t, J = 7.20 Hz), 7.46 (2H, t, J = 7.05 Hz), 7.33–7. 4 
( 0H, m), 4.63–4.58 ( H, m), 4.42–4.39 (2H, m), 3. 6 (2H, t, J = 
7.65 Hz), 2.98–2.9  ( H, m), 2.50 ( H, sep, J = 3.39 Hz), 2.04–
.74 (4H, m), .64– .32 (4H, m); 3C NMR (CD3OD, 75MHz, ; 
ppm) 74.2, 70.4, 39.9, 39.4, 35.2, 33.0, 29.8, 29.6, 29.6, 
28.6, 28.6, 28.3, 28. , 27.5, 55.2, 44.2, 39. , 32.5, 26.7, 24.2, 
22.5, 3.4; HRMS (FAB) calcd for C29H34O2N3+, 456.265 , found, 
456.2654; HPLC tR = 8.72 min, purity 00%. 
( S,2R)-NCD 8 hydrochloride salts: colorless crystals (74.9 mg, 
55%); H NMR (CD3OD, 300MHz, ; ppm) 7.89–7.85 (2H, m), 
7.55 ( H, t, J = 7.35 Hz), 7.46 (2H, t, J = 7.35 Hz), 7.33–7. 4 
( 0H, m), 4.63–4.58 ( H, m), 4.40 (2H, d, J = .86 Hz), 3. 9–
3. 2 (2H, m), 2.93 ( H, quin, J = 2.93 Hz), 2.45 ( H, sep, J = 3.39 
Hz), 2.04- .72 (4H, m), .63– .32 (4H, m); 3C NMR (CD3OD, 
75MHz, ; ppm) 74.2, 70.4, 39.8, 39.3, 35.2, 33.0, 29.8, 
29.6, 29.6, 28.6, 28.5, 28.3, 28. , 27.4, 55. , 44.2, 39. , 
32.5, 26.7, 24.2, 22.5, 3.4; HRMS (FAB) calcd for C29H34O2N3+, 
456.265 , found, 456.2625; HPLC tR = 8.94 min, purity 96%. 
( R,2S)-NCD25 hydrochloride salt: colorless crystals (4 .0 mg, 
38%); m.p. 28– 3  °C ; H NMR (CD3OD, 300MHz, ; ppm) 
7.96 (2H, d, J = 8.70 Hz), 7.73 (2H, d, J = 8.40 Hz), 7.67 (2H, d, 
J = 7.20 Hz ), 7.47 (2H, t, J = 7.20 Hz), 7.38 ( H, t, J = 7.20 Hz), 
7.34–7. 5 ( 0H, m),  4.66–4.6  ( H, m), 4.42 (2H, s), 3.22–3. 3 
(2H, m), 2.94 ( H, quin, J = 3.90 Hz), 2.47 ( H, sep, J = 3.40 
Hz), 2.02– .72 (4H, m), .65– .33 (4H, m); 3C NMR (CD3OD, 
75MHz, ; ppm) 74.2, 70. , 46. , 4 .2, 39.9, 39.3, 33.8, 
30. , 29.8, 29.6, 29.3, 28.6, 28.3, 28.2, 28. , 27.5, 55.2, 
44.2, 39. , 32.6, 26.8, 24.2, 22.6, 3.5; HRMS (FAB) calcd for 
C35H38O2N3+, 532.2964, found, 532.2969; HPLC tR = 2.54 min, 
purity 96.5%. 
( S,2R)-NCD25 hydrochloride salt: colorless crystals (42.4 mg, 
39%); m.p. 2 – 23 °C; H NMR (CD3OD, 300MHz, ; ppm) 
7.96 (2H, d, J = 8.70 Hz), 7.73 (2H, d, J = 8.70 Hz), 7.67 (2H, d, 
J = 6.90 Hz), 7.47 (2H, t, J = 7.35 Hz), 7.38 ( H, t, J = 7.35 Hz), 
7.33–7. 4 ( 0H, m), 4.66–4.6  ( H, m), 4.42 (2H, s), 3.22–3. 2 
(2H, m), 2.95 ( H, quin, J = 3.98 Hz), 2.46 ( H, sep, J = 3.35 
Hz), 2.04– .72 (4H, m), .64– .33 (4H, m); 3C NMR (CD3OD, 
75MHz, ; ppm) 74.2, 70. , 46. , 4 .2, 39.9, 39.4, 33.8, 
30. , 29.8, 29.6, 29.3, 28.6, 28.3, 28.2, 28. , 27.5, 55. , 
44.2, 39.2, 32.6, 26.8, 24.2, 22.6, 3.5; HRMS (FAB) calcd for 
C35H38O2N3+, 532.2964, found, 532.2968; Anal. calcd. for C35H38Cl 
N3O2·4/5H2O: C, 72. 6; H, 6.85; N, 7.2 , found: C, 72.03; H, 
6.54; N, 7. 4; HPLC tR = 2.5  min, purity 95.9%.  
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( R, 2S)-NCD4  hydrochloride salt: colorless crystals (62.6 mg, 
62%); m.p. 66– 70 °C; H NMR (CD3OD, 300MHz, ; ppm) 
7.97 (2H, d, J = 8.70 Hz), 7.75–7. 5 ( 6H, m), 4.66–4.6  ( H, 
m), 4.49 (2H, s), 3.2 –3. 4 (2H, m), 2.95 ( H, quin, J = 3.90 Hz), 
2.46 ( H, sep, J = 3.40 Hz), 2.05– .73 (4H, m), .65– .33 (4H, 
m); 3C NMR (CD3OD, 75MHz, ; ppm) 74.5, 70. , 46. , 
4 .5, 4 .2, 39.3, 33.7, 32.3, 30.4, 30. , 29.8, 29.2, 
29.2, 28. , 28. , 27.4, 25.2, 25. , 25.0, 25.0, 55.2, 43.6, 
39. , 32.4, 26.7, 24.2, 22.5, 3.4.; HRMS (FAB) calcd. for 
C36H37F3O2N3+, 600.2838, found, 600.284 ; Anal. Calcd. for 
C36H37ClF3 N3O2: C, 67.97; H, 5.86; N, 6.6 . Found: C, 67.6 ; H, 
5.64; N, 6.39.; HPLC tR = 4.55 min, purity 97.5%. 
( S, 2R)-NCD4  hydrochloride salt: colorless crystals (62.4 mg, 
68%); m.p. 34– 36 °C ; H NMR (CD3OD, 300MHz, ; ppm) 
7.97 (2H, d, J = 8.49 Hz), 7.75–7. 5 ( 6H, m), 4.66–4.6  ( H, 
m), 4.49 (2H, s), 3.22–3. 4 (2H, m), 2.95 ( H, quin, J = 3.90 Hz), 
2.46 ( H, sep, J = 3.40 Hz), 2.04– .74 (4H, m), .64– .33 (4H, 
m); 3C NMR (CD3OD, 75MHz, ; ppm) 74.5, 70. , 46. , 
4 .5, 4 .3, 39.3, 33.8, 32.3, 30.4, 30. , 29.8, 29.3, 
29.2, 28.2, 28. , 27.5, 25.2, 25. , 25.0, 25.0, 55.2, 43.7, 
39. , 32.4, 26.8, 24.3, 22.6, 3.5; HRMS (FAB) calcd. for 
C36H37F3O2N3+, 600.2838, found, 600.2843; Anal. Calcd. for 
C36H37ClF3 N3O2: C, 67.97; H, 5.86; N, 6.6 . Found: C, 67.89; H, 
5.64; N, 6.6 .; HPLC tR = 4.54 min, purity 98. %. 
Chart 2.  Preparation of optically pure trans-PCPA. 
 
Chart 3. Synthesis of optically pure LSD1 inactivators. 
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The LSD  inhibition assay was carried out according to the 
method reported in ref. 2 . 
 
Docking was performed using Molegro Virtual Docker 5.0 
software. Coordinates of LSD  completed with FAD-N-propargyl 
lysine peptide adduct were taken from the Brookhaven Protein Data 
Bank (PDB code 2UXN). Water molecules, cofactors and a peptide 
substrate were removed, and FAD was converted to a cofactor. The 
structure of NCD 8, NCD25 and NCD4  bound to LSD  was 
constructed by MolDock, which is based on a heuristic search 
algorithm that combines differential evolution with a cavity prediction 
algorithm. The docking parameters were as follow: Grid Resolution: 
0.30, Max iterations: 500, Population size: 50, Energy threshold: 
00.00, Simplex evolution: 300 (Max steps) and .00 (Neighbour 
distance factor), Search space: (X, Y, Z) = (65.64, 47.97, 35.60) 
with radius 0, distance constraints (for N atom of cyclopropylamine 
of NCD 8, NCD25, NCD4 ): constraint center (X, Y, Z) = 
(64.5 , 54. , 34.83) with hard constraint between minimum 0 to 
maximum 2.0. 
 
Results and Discussion 
 
Individual stereoisomers were synthesized as shown in Charts 2 
and 3. First, trans-(±) PCPA was resolved into D-tartaric acid salt  
and the salt was recrystallized. Then, simple deprotonation with 
sodium hydroxide liberated free ( S,2R)-PCPA. On the other hand, 
( R,2S)-PCPA was collected from the mother liquid by extraction 
with ether, salt formation (salt 2) with L-tartaric acid, recrystallization 
of the D-tartaric acid salt, and extraction with ether in sequential 
order. Finally, each enantiomer was reacted with the corresponding 
mesylate compound 3 [2 ] in the presence of potassium carbonate to 
give optically pure NCD 8, NCD25, and NCD4  in 7–68% yield. 
 

 
We examined the LSD inhibitory activities of optically active 
NCD 8, NCD25, and NCD4  by means of a horseradish 
peroxidase-coupled assay [27] (Table ). As expected, the 
diastereomers of NCD 8, NCD25, and NCD4  inhibited LSD  
more strongly than PCPA. Importantly, there were differences in 
LSD  inhibitory activity between ( R,2S)- and ( S,2R)-isomers. The 
IC50 values of ( R,2S)-NCD 8, ( R,2S)-NCD25, and ( S,2R)-
NCD4  were lower than those of ( S,2R)-NCD 8, ( S,2R)-
NCD25, and ( R,2S)-NCD4 , respectively. The results revealed that 
the ( R,2S)-isomers are superior to the ( S,2R)-isomers with respect 
to LSD  inhibition by NCD 8 and NCD25. On the other hand, the 
( S,2R)-isomer of NCD4  was more potent than its ( R,2S)-isomer. 
Although we could not conclude which isomer is more potent, we 
found that the LSD  inhibitory activities of the ( S,2R)-isomer and 
the ( R,2S)-isomer are dependent on the structure of the R group in 
the NCD series compounds (Chart 3). 
 
To verify the relationship between the stereochemistry and the 
LSD  inhibitory activity of the NCD series compounds, we 
performed binding simulation of the compounds to LSD  by using 
Molegro Virtual Docker 5.0 software. The simulation was performed 
based on the reported X-ray structure of LSD  [28] and under the 
condition that the cyclopropylamine group of NCD 8, NCD25, and 
NCD4  was fixed to the position where it could react with FAD. 
The results of the simulation indicated that the interaction with 
amino acid residues in the three hydrophobic pockets (pockets –3, 
Figure ) and the formation of one hydrogen bond are important for 
the LSD  inhibitory activity of optically pure LSD  inactivators as 
discussed in more detail below. 
 
A) 
 
 
B) 
 
 
 
 
 
 
 
Figure 1. (A) View of the three hydrophobic pockets in the LSD1 catalytic 
core. Each pocket is drawn as a green sphere. Pocket 1 is formed by Phe 
382, Leu 386, Leu 536, Phe 538, Ala 539, Trp 552, and Phe 692. Pocket 2 is 
formed by Val 333, Ile 356, Leu 677, Leu 693, and Trp 695. Pocket 3 is 
formed by Phe 560, Tyr 807, Pro 808, Ala 809, Thr 810 (methyl group), and 
His 812. (B) Schematic diagram of Figure 1A. 
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First, we simulated the binding mode of NCD 8. In the lowest 
energy complex of ( R,2S)-NCD 8 with LSD , as described in our 
previous report [2 ], the benzoyl group and the benzyl group of 
( R,2S)-NCD 8 could interact with hydrophobic amino acid 
residues in two of the three pockets (Figure 2A and 2C). The benzoyl 
group of ( R,2S)-NCD 8 was positioned in pocket  formed by Phe 
382, Leu 386, Leu 536, Phe 538, Ala 539, Trp 552, and Phe 692, 
and the benzyl group was positioned in pocket 2 formed by Val 333, 
Ile 356, Leu 677, Leu 693, and Trp 695. In addition, ( R,2S)-
NCD 8 could form a hydrogen bond with the oxygen atom of Tyr 
76  (Figure 2B and 2C). On the other hand, ( S,2R)-NCD 8 could 
not interact with any amino acid residues in the three hydrophobic 
pockets (Figure 2D–F), although it could form a hydrogen bond with 
Tyr 76  (Figure 2E). Those interactions with amino acid residues in 
the hydrophobic pockets may be the reason why ( R,2S)-NCD 8 is 
more potent than its ( S,2R)-isomer. 
Figure 2. Views of NCD18 docked to LSD1 catalytic core. (A) and (B) Views of the binding conformation of (1R,2S)-NCD18 (ball and stick). The yellow broken line 
indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the O atom of the side chain of 
Tyr 761. (C) Schematic diagram of binding of (1R,2S)-NCD18. (D) and (E) Views of the binding conformation of (1S,2R)-NCD18 (ball and stick). The yellow broken 
line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the O atom of the side chain 
of Tyr 761. (F) Schematic diagram of binding of (1S,2R)-NCD18. 
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Next, the modeling of NCD25 binding with LSD  was 
conducted. As shown in Figure 3A and 3C, the binding model of 
NCD25 was different from that of NCD 8, i.e., the biphenyl group 
of ( R,2S)-NCD25 could interact with pocket 3 formed by Phe 560, 
Tyr 807, Pro 808, Ala 809, Thr 8 0 (methyl group), and His 8 2, 
although the benzyl group could interact with the hydrophobic amino 
acid residues in pocket 2 as in the case of ( R,2S)-NCD 8 (Figure 
2A and 2C). In the case of ( S,2R)-NCD25, the biphenyl group was 
positioned in pocket 2, but the benzyl group did not interact with any 
of the three pockets (Figure 3D and 3F). ( R,2S)-NCD25 and 
( S,2R)-NCD25 could interact with the oxygen atom of Tyr 76  
and the carbonyl oxygen of Ala 809 via a hydrogen bond (Figure 3B 
and 3E), respectively. Taken together, ( R,2S)-NCD25 could 
interact with two hydrophobic pockets whereas ( S,2R)-NCD25 
could interact with only one hydrophobic pocket. This may be the 
reason why the LSD  inhibitory activity of ( R,2S)-NCD25 is 
superior to that of ( S,2R)-NCD25.  
 
Figure 3. View of NCD25 docked to LSD1 catalytic core. (A) and (B) Views of the binding conformation of (1R,2S)-NCD25 (ball and stick). The yellow broken line 
indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the O atom of the side chain of 
Tyr 761. (C) Schematic diagram of binding of (1R,2S)-NCD25. (D) and (E) Views of the binding conformation of (1S,2R)-NCD25 (ball and stick). The yellow broken 
line indicates a hydrogen bond and the value indicates distance between the H atom of the amino group of cyclopropylamine and the carbonyl oxygen of Ala 
809. (F) Schematic diagram of binding of (1S,2R)-NCD25. 
 
Optically Active Lysine-PCPA conjugates 
6 
Volume No: 9, Issue: 14, e201402002 Computational and Structural Biotechnology Journal | www.csbj.org 
 
 
 
 
 
 
 
Finally, the modeling of NCD4  binding with LSD  was carried 
out as in the case of NCD 8 and NCD25. Although the biphenyl 
group of ( R,2S)-NCD4  could interact with the hydrophobic 
amino acid residues in pocket , ( R,2S)-NCD4  could not form 
any hydrogen bonds (Figure 4A and 4B). However, as in the case of 
( R,2S)-NCD25 (Figure 3A and 3C), the biphenyl group and the 
trifluoromethylbenzyl group of ( S,2R)-NCD4  could interact with 
the amino acid residues in pocket 2 and pocket 3, respectively (Figure 
4D and 4F). In addition, ( S,2R)-NCD4  could interact with the 
carbonyl oxygen of Ala 809 via a hydrogen bond (Figure 4E). The 
experimental results that ( S,2R)-NCD4  is more potent than its 
( R,2S)-isomer could be explained by the calculated results.  
The difference between NCD25 and NCD4  is the presence of 
m-trifluoromethyl group at the benzyl group (Chart ). The 
introduction of this substituent to ( R,2S)-NCD25 could cause the 
sterical hinderance between the trifluoromethyl group and Leu 677 or 
Leu 693 in pocket 2 (Figure 3A and 3C). Therefore, m-
trifluoromethylated benzyl group of ( R,2S)-NCD4  could not be 
Figure 4. View of NCD41 docked to LSD1 catalytic core. (A) and (B) Views of the binding conformation of (1R,2S)-NCD41 (ball and stick). (C) Schematic diagram 
of binding of (1R,2S)-NCD41. (D) and (E) Views of the binding conformation of (1S,2R)-NCD41 (ball and stick). The yellow dotted line indicates a hydrogen bond 
and the value indicates distance between the H atom of the amino group of cyclopropylamine and the carbonyl oxygen of Ala 809. (F) Schematic diagram of 
binding of (1S,2R)-NCD41. 
 
Optically Active Lysine-PCPA conjugates 
7 
Volume No: 9, Issue: 14, e201402002 Computational and Structural Biotechnology Journal | www.csbj.org 
positioned in pocket 2 Instead, the m-trifluoromethylated benzyl 
group of ( R,2S)-NCD4  was located in pocket 3 (Figure 4D and 
4F) which is too large to appropriately accommodate the 
unsubstituted benzyl group of ( R,2S)-NCD25. This may be the 
reason why the inhibitory activity of ( R,2S)-NCD4  is superior to 
that of ( R,2S)-NCD25. 
The interaction of each isomer with amino acid residues in the 
hydrophobic pockets and the hydrogen bond formation are 
summarized as follows: (i) ( R,2S)-NCD 8, ( R,2S)-NCD25, and 
( S,2R)-NCD4  could interact with amino acid residues in two 
hydrophobic pockets and form one hydrogen bond, (ii) ( S,2R)-
NCD25 could interact with amino acid residues in only one 
hydrophobic pocket and form one hydrogen bond, (iii) ( S,2R)-
NCD 8 could form one hydrogen bond, and (iv) ( R,2S)-NCD4  
could interact with amino acid residues in only one hydrophobic 
pocket. Considering the relationship between the stereochemistry and 
the LSD  inhibitory activity of the NCD series compounds, 
compounds that could interact with amino acid residues in two 
pockets and form a hydrogen bond showed high LSD  inhibitory 
activities. In other words, the stereochemistry of the PCPA moiety 
could affect LSD  inhibitory activity through the interaction of the 
two aromatic groups with hydrophobic amino acid residues and the 
hydrogen bond formation. 
 
Conclusion 
 
In conclusion, we synthesized optically active ( R,2S)-isomers 
and ( S,2R)-isomers of NCD 8, NCD25, and NCD4 , and 
evaluated their LSD  inhibitory activities in enzyme assays. The 
( R,2S)-isomers of NCD 8 and NCD25 were more potent than 
their ( S,2R)-isomers. On the other hand, the ( S,2R)-isomer of 
NCD4  was more potent than its ( R,2S)-isomer. In addition, the 
binding simulation indicated that the potent NCD series compounds 
can interact with amino acid residues in the two hydrophobic pockets 
and form a hydrogen bond in the LSD  active site, and that the 
stereochemistry of PCPA affects LSD  inhibitory activity. These 
ﬁndings will be useful for the further development of PCPA-based 
LSD  inhibitors and LSD -targeted therapy. 
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